![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir (BMS-650032, ASV)
|
|
|
Reported by Jules Levin
AASLD 2012 Nov 9-12 Boston MA
Eley T,1 He B,1 Li J,1 Colston E,1 Child M,1 Bedford BR,1 Kandoussi H,1 Wind-Rotolo M,1
Pasquinelli C,1 DeMicco MP,2 Marbury TC,3 Bertz RJ1
1Bristol-Myers Squibb Research and Development, Princeton, NJ; 2Advanced Clinical Research Institute, Anaheim, CA; 3Orlando Clinical Research Center, Orlando, FL
AASLD: Phase 2b Study of the Interferon-Free and Ribavirin-Free Combination of Daclatasvir, Asunaprevir, and BMS-791325 for 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 1 Infection - (11/05/13)
AASLD: BMS at AASLD - (11/18/13)
![AASLD1.gif](../images/120413/AASLD1.gif)
![AASLD2.gif](../images/120413/AASLD2.gif)
![AASLD3.gif](../images/120413/AASLD3.gif)
![AASLD4.gif](../images/120413/AASLD4.gif)
![AASLD5.gif](../images/120413/AASLD5.gif)
![AASLD6.gif](../images/120413/AASLD6.gif)
![AASLD7.gif](../images/120413/AASLD7.gif)
![AASLD8.gif](../images/120413/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|